Atossa Therapeutics announced data on new compounds potentially effective in combination with (Z)-endoxifen for breast cancer treatment.
Quiver AI Summary
Atossa Therapeutics, Inc. announced the discovery of compounds that may enhance the effectiveness of (Z)-endoxifen for breast cancer treatment, as detailed in a poster presentation at the 2024 San Antonio Breast Cancer Symposium. The research utilized insilico and chemical screening methods to identify compounds that inhibit key enzymes linked to cancer cell proliferation and survival. The findings showed that combining these novel compounds with (Z)-endoxifen induced greater cell death in human breast cancer cells than either agent alone. The company's president expressed optimism about these discoveries, highlighting a commitment to improving breast cancer therapies. Atossa is also advancing a proprietary oral formulation of (Z)-endoxifen, demonstrating a good safety profile in early clinical studies, and is currently investigating its efficacy in multiple Phase 2 trials.
Potential Positives
- Announcement of the discovery of new compounds that may synergistically enhance the efficacy of (Z)-endoxifen for breast cancer treatment, demonstrating ongoing research advancements.
- Presentation of these findings at the prestigious 2024 San Antonio Breast Cancer Symposium, increasing visibility and credibility within the oncology research community.
- Potential for combination therapies to significantly improve outcomes for breast cancer patients, highlighting the company’s commitment to addressing significant unmet medical needs in oncology.
- Ongoing clinical development of (Z)-endoxifen, supported by a strong patent portfolio, indicating a secure position for future innovation and market opportunity.
Potential Negatives
- Potential reliance on the success of (Z)-endoxifen, which is still undergoing clinical trials, creates uncertainty regarding future revenue and market position.
- The necessity for further studies before confirming the efficacy of the newly discovered compounds may imply prolonged development timelines and associated costs.
- Forward-looking statements indicate significant risks and uncertainties, including potential regulatory hurdles and challenges with trial completions and patient enrollment, which could affect Atossa's strategic objectives.
FAQ
What is the main focus of Atossa Therapeutics?
Atossa Therapeutics focuses on developing innovative medicines for oncology, particularly in the treatment and prevention of breast cancer.
What are the new compounds discovered by Atossa Therapeutics?
Atossa has identified compounds that may synergize with (Z)-endoxifen to inhibit specific enzymes and proteins involved in breast cancer.
Where will the new data be presented?
The data will be presented at the 2024 San Antonio Breast Cancer Symposium (SABCS) on December 13, 2024.
What is (Z)-endoxifen?
(Z)-endoxifen is a potent Selective Estrogen Receptor Modulator (SERM) that targets estrogen receptors and shows efficacy against hormone-resistant tumors.
What are the benefits of Atossa's (Z)-endoxifen formulation?
Atossa's formulation of (Z)-endoxifen bypasses liver metabolism, providing therapeutic concentrations without converting to an inactive form.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ATOS Hedge Fund Activity
We have seen 37 institutional investors add shares of $ATOS stock to their portfolio, and 45 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- LAURION CAPITAL MANAGEMENT LP removed 2,225,800 shares (-100.0%) from their portfolio in Q2 2024
- NORTHERN TRUST CORP added 686,991 shares (+257.1%) to their portfolio in Q3 2024
- BLACKROCK, INC. added 470,575 shares (+5.1%) to their portfolio in Q3 2024
- HRT FINANCIAL LP removed 291,421 shares (-100.0%) from their portfolio in Q2 2024
- RENAISSANCE TECHNOLOGIES LLC removed 240,840 shares (-15.5%) from their portfolio in Q3 2024
- GOLDMAN SACHS GROUP INC added 146,463 shares (+142.7%) to their portfolio in Q3 2024
- POINT72 ASIA (SINGAPORE) PTE. LTD. removed 140,858 shares (-100.0%) from their portfolio in Q2 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SEATTLE, Dec. 12, 2024 (GLOBE NEWSWIRE) --
Atossa Therapeutics, Inc.
(Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced data describing the discovery of compounds that may be synergistic with (Z)-endoxifen and that could potentially be used in combinations for the treatment of breast cancer. The data is being presented in a poster at the 2024 San Antonio Breast Cancer Symposium (SABCS) on December 13, 2024.
The poster, titled, “Discovery of molecules synergistic with (Z)-endoxifen for the treatment of breast cancer,” describes the use of two independent approaches, insilico and chemical screening, which led to the identification of compounds that may be used to inhibit enzymes and proteins which play a role in, among other things, uncontrolled cell proliferation and tumor survival (e.g., DNA topoisomerase, CDK, mTOR/PI3K and AKT) and which may synergize with (Z)-endoxifen. The combination of these newly discovered compounds was shown to induce cell death in MCF-7 cells, a widely used human breast cancer cell line in scientific research, at levels greater than with either agent alone. In particular, several inhibitors of MEK, PI3K and AKT showed synergistic potential in reducing MCF-7 cell viability. Together, these data suggest that combination therapies with (Z)-endoxifen and agents targeting topoisomerase, CDK, mTOR/PI3K and AKT have potential in the treatment of breast cancer but require further study.
“The discovery of new, synergistic compounds that could potentially complement the cancer preventing and fighting mechanism of (Z)-endoxifen showcases our continuing mission to transform the breast cancer paradigm,” said Steven Quay, M.D., Ph.D., Atossa’s President and Chief Executive Officer. “I congratulate our research team and collaborators on these discoveries as we continue to enlist advanced techniques to bring novel compounds and combinations with significant anti-cancer properties to the treatment of these challenging cancers.”
Poster Details
Title: P4-05-22 Discovery of Molecules Synergistic with (Z)-endoxifen for the
Treatment of Breast Cancer
Description:
Presents findings from a study exploring synergistic combinations of (Z)-endoxifen with other compounds for enhanced treatment efficacy.
Presentation Details:
Daniela Hühn, 5:30-7:00 pm, December 13, 2024
A link to the poster presentation will be made available on Atossa Therapeutics’ website at the time of the presentation. For additional information, please visit the SABCS website:
https://sabcs.org
.
About (Z)-Endoxifen
(Z)-endoxifen is the most potent Selective Estrogen Receptor Modulator (SERM) for estrogen receptor inhibition and also causes estrogen receptor degradation. It has also been shown to have efficacy in the setting of patients with tumor resistance to other hormonal treatments. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCβ1, a known oncogenic protein, at clinically attainable blood concentrations. Finally, (Z)-endoxifen appears to deliver similar or even greater bone agonistic effects while resulting in little or no endometrial proliferative effects compared with standard treatments, like tamoxifen.
Atossa is developing a proprietary oral formulation of (Z)-endoxifen that does not require liver metabolism to achieve therapeutic concentrations and is encapsulated to bypass the stomach, as acidic conditions in the stomach convert a significant proportion of (Z)-endoxifen to the inactive (E)-endoxifen. Atossa’s (Z)-endoxifen has been shown to be well tolerated in Phase 1 studies and in a small Phase 2 study of women with breast cancer. (Z)-endoxifen is currently being studied in four Phase 2 trials: one in healthy women with measurable breast density, one in women diagnosed with ductal carcinoma in situ, and two other studies including the EVANGELINE study in women with ER+/HER2- breast cancer. Atossa’s (Z)-endoxifen is protected by four issued U.S. patents and numerous pending patent applications.
About Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. For more information, please visit
www.atossatherapeutics.com
.
FORWARD LOOKING STATEMENTS
This press release contains certain information that may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We may identify these forward-looking statements by the use of words such as “expect,” “potential,” “continue,” “may,” “will,” “should,” “could,” “would,” “seek,” “intend,” “plan,” “estimate,” “anticipate,” “believe,” “design,” “predict,” “future,” or other comparable words. All statements made in this press release that are not statements of historical fact, including statements regarding data related to the (Z)-endoxifen program, the safety, tolerability and efficacy of (Z)-endoxifen, the potential of (Z)-endoxifen as a breast cancer prevention and treatment agent, the expected design and enrollment of trials and timing of data and related publications, and the potential milestones and growth opportunities for the Company, are forward-looking statements. Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results, outcomes, or the timing of actual results or outcomes, to differ materially from those projected or anticipated, including risks and uncertainties associated with: macroeconomic conditions and increasing geopolitical instability; the expected timing of releasing data; any variation between interim or preliminary and final clinical results or analysis; actions and inactions by the FDA and foreign regulatory bodies; the outcome or timing of regulatory approvals needed by Atossa, including those needed to continue our planned (Z)-endoxifen trials; our ability to satisfy regulatory requirements; our ability to remain compliant with the continued listing requirements of the Nasdaq Stock Market; our ability to successfully develop and commercialize new therapeutics; the success, costs and timing of our development activities, including our ability to successfully initiate or complete our clinical trials, including our (Z)-endoxifen trials; our anticipated rate of patient enrollment; our ability to contract with third-parties and their ability to perform adequately; our estimates on the size and characteristics of our potential markets; our ability to successfully defend litigation and other similar complaints and to establish and maintain intellectual property rights covering our products; whether we can successfully complete our clinical trial of oral (Z)-endoxifen in women with mammographic breast density and our trials of (Z)-endoxifen in women with breast cancer, and whether the studies will meet their objectives; our expectations as to future financial performance, expense levels and capital sources, including our ability to raise capital; our ability to attract and retain key personnel; our anticipated working capital needs and expectations around the sufficiency of our cash reserves; and other risks and uncertainties detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its Annual Reports on Form 10-K and Quarterly Reports on 10-Q. Forward-looking statements are presented as of the date of this press release. Except as required by law, we do not intend to update any forward-looking statements, whether as a result of new information, future events or circumstances or otherwise.
Contact:
Michael Parks
VP, Investor and Public Relations
484-356-7105
michael.parks@atossainc.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
